Skip to main content

Hematocrit Within Normal Range With Testosterone Gender-Affirming Therapy

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 27, 2023.

By Elana Gotkine HealthDay Reporter

MONDAY, Nov. 27, 2023 -- For people using testosterone as gender-affirming hormone therapy (GAHT), mean hematocrit varies from 41.84 to 45.68 percent, which is within the normal range, according to a study published online Nov. 27 in the Journal of Clinical Endocrinology & Metabolism.

Nithya Krishnamurthy, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues examined the effect of using exogenous testosterone as GAHT on hematocrit in 6,670 patients who were prescribed testosterone through Plume.

Of the patients, 8.4, 2.7, and 0.9 percent had a hematocrit ≥50 percent, ≥52 percent, and ≥54 percent, respectively. The researchers found that hematocrit varied significantly between different clinically relevant testosterone thresholds (T <50 versus 50 to 299 versus 300 to 999 versus ≥1,000 ng/dL) and on comparison of serum testosterone in increments of 50 ng/dL within the target range for males (300 to 1,000 ng/dL). The range of mean hematocrit was from 41.84 percent (T <50 ng/dL) to 45.68 percent (T 900 to 949 ng/dL). Higher mean hematocrit was seen for patients on intramuscular testosterone versus transdermal testosterone (44.96 versus 43.41 percent). When controlling for each other, both route of administration and testosterone level had significant associations with hematocrit.

"It's noteworthy that in the largest North American cohort reported to date, less than 1 percent of transmasculine individuals had a hematocrit level where medical interventions might be required," Krishnamurthy said in a statement. "These results should help providers feel more comfortable prescribing testosterone as part of GAHT."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care

TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.